Prognostic Gene Expression Tests for Early Stage Breast Cancer
The presentation will discuss prognostic gene expression tests for use in early stage breast cancer and the level of scientific evidence that has been generated to date for each test.
Originally presented on May 15, 2014 in Salt Lake City, Utah
Philip S. Bernard, MD
Medical Director, Molecular Oncology, ARUP Laboratories
Investigator, Huntsman Cancer Center
Associate Professor of Pathology, University of Utah School of Medicine
Dr. Bernard is a medical director of Molecular Oncology at ARUP Laboratories and an associate professor of pathology at the University of Utah School of Medicine. As an investigator at the Huntsman Cancer Center, Dr. Bernard’s laboratory uses comprehensive genomic analyses to identify and translate biomarkers into clinical care for cancer patients. Dr. Bernard received his MD from and completed his postdoctoral training at the University of Utah and is certified in clinical pathology by the American Board of Pathology.
After this presentation, participants will be able to:
- Review differences between prognostic and predictive tests.
- Review gene expression tests for prognosis in early stage breast cancer clinically available in 2014.
- Review levels of evidence for using different tests based on clinical indications.
- Review differences between research assays, Laboratory Developed Tests (LDT), and FDA-cleared tests.
University of Utah School of Medicine, Department of Pathology, and ARUP Laboratories